1
|
Melero I, Calvo E, Goebeler ME, Garralda E, Dummer R, Rodríguez-Ruiz M, De Miguel M, Sayehli C, Casal GA, Ramelyte E, Schuler M, Gromke T, Sanmamed M, Moreno I, Bargou R, Lostes M, Maul JT, Richly H, Fettes P, Klar K, Schuberth-Wagner C, Haake M, Wischhusen J, Leo E. Abstract P06-01: A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced stage solid tumors (Acronym: GDFATHER). Mol Cancer Ther 2021. [DOI: 10.1158/1535-7163.targ-21-p06-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Growth and differentiation factor 15 (GDF-15) is a TGF-β superfamily member physiologically expressed mainly in placenta and linked to feto-maternal tolerance. Under pathophysiologic conditions, prevention of excessive immune cell infiltration during tissue damage and cachexia induction have been ascribed to GDF-15. A recent study [Haake et al. AACR2020; Abstract #5597] elucidated a mechanism by which GDF-15 inhibits LFA-1 activation on CD8+ T cells, thus interfering with effector T cell recruitment to tissues. Importantly, several cancer entities secrete high levels of GDF-15, correlating with poor prognosis and reduced overall survival [reviewed in Front Immunol 2020 May 19;11:951]. To block this effect the GDF-15 neutralizing antibody CTL-002 was generated. In preclinical models CTL-002 demonstrated potent effector T cell shifting into tumor tissue by neutralizing GDF-15 and enhancing response to checkpoint inhibitor therapy. Methods: This is a phase 1, first-in-human (FIH), two-part, open-label clinical trial of intravenous (IV) administration of CTL-002 given as monotherapy and in combination with an anti-PD-1 antibody in subjects with advanced-stage, relapsed/refractory solid tumors who relapsed on or were refractory to a prior anti-PD-1/PD-L1 therapy. Eligible subjects have exhausted all available approved standard treatments, including prior anti-PD1/-PD-L1 treatment, and present with a biopsy-accessible tumor for serial biopsy taking. The trial is termed GDFATHER, for “GDF-15 Antibody-mediaTed Effector cell Relocation”. Main endpoints are safety of CTL-002 monotherapy and CTL-002 combination with an anti-PD-1 antibody, pharmacokinetics, pharmacodynamics (e.g., degree of GDF-15 neutralization achieved and change in immune-cell number and composition in the tumor tissue) as well as preliminary clinical efficacy (tumor mass reduction; anticachexia effect). In part A of the trial (dose escalation) up to 24 subjects will receive escalating doses of CTL-002 IV (0.3 – 20 mg/kg) in a „mono-followed-by-combination“-design with CTL-002 given as monotherapy and followed by combination with an anti-PD-1 checkpoint inhibitor. In part B (expansion) up to 5 cohorts with up to 25 subjects per cohort with defined tumor entities expected to be GDF-15 dependent will be treated to determine the recommended phase 2 dose (RP2D) and further evaluate safety and preliminary efficacy of CTL-002 monotherapy and the combination. The study was initiated in December 2020 and enrolled the first patient on Dec 09, 2020. Cohort 4 is ongoing at time of submission (07/2021) and so far no DLT has occurred. Updated safety, biomarker and response assessments will be reported. The ClinicalTrials.gov Identifier is NCT04725474.
Citation Format: Ignacio Melero, Emiliano Calvo, Maria-Elisabeth Goebeler, Elena Garralda, Reinhard Dummer, María Rodríguez-Ruiz, María De Miguel, Cyrus Sayehli, Guzman Alonso Casal, Egle Ramelyte, Martin Schuler, Tanja Gromke, Miguel Sanmamed, Irene Moreno, Ralf Bargou, Maria Lostes, Julia-Tatjana Maul, Heike Richly, Petra Fettes, Kathrin Klar, Christine Schuberth-Wagner, Markus Haake, Joerg Wischhusen, Eugen Leo. A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced stage solid tumors (Acronym: GDFATHER) [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2021 Oct 7-10. Philadelphia (PA): AACR; Mol Cancer Ther 2021;20(12 Suppl):Abstract nr P06-01.
Collapse
Affiliation(s)
| | - Emiliano Calvo
- 2Hospital Universitario HM Sanchinarro START, Madrid, Spain,
| | | | | | | | | | - María De Miguel
- 2Hospital Universitario HM Sanchinarro START, Madrid, Spain,
| | | | | | | | | | | | | | - Irene Moreno
- 2Hospital Universitario HM Sanchinarro START, Madrid, Spain,
| | - Ralf Bargou
- 3University Hospital Würzburg, Würzburg, Germany,
| | - Maria Lostes
- 4Hospital Universitari Vall d'Hebron, Barcelona, Spain,
| | | | | | | | | | | | | | | | - Eugen Leo
- 7CatalYm GmbH, Planegg-Martinsried, Germany,
| |
Collapse
|
2
|
Vargas T, Moreno-Rubio J, Herranz J, Cejas P, Molina S, Mendiola M, Burgos E, Custodio AB, De Miguel M, Martín-Hernández R, Reglero G, Feliu J, Ramírez de Molina A. 3'UTR Polymorphism in ACSL1 Gene Correlates with Expression Levels and Poor Clinical Outcome in Colon Cancer Patients. PLoS One 2016; 11:e0168423. [PMID: 27992526 PMCID: PMC5167383 DOI: 10.1371/journal.pone.0168423] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2016] [Accepted: 11/30/2016] [Indexed: 12/18/2022] Open
Abstract
Strong evidence suggests that lipid metabolism (LM) has an essential role in tumor growth to support special energetic and structural requirements of tumor cells. Recently, overexpression of LM-related genes, apolipoproteins related to metabolic syndrome, and ACSL/SCD network involved in fatty acid activation have been proposed as prognostic markers of colon cancer (CC). Furthermore, activation of this latter lipid network has been recently demonstrated to confer invasive and stem cell properties to tumor cells promoting tumor aggressiveness and patient relapse. With the aim of elucidating whether any genetic variation within these genes could influence basal expression levels and consequent susceptibility to relapse, we genotype, in 284 CC patients, 57 polymorphisms located in the 7 genes of these lipid networks previously associated with worse clinical outcome of CC patients (ABCA1, ACSL1, AGPAT1, APOA2, APOC1, APOC2 and SCD), some of them related to CC aggressiveness. After adjusting with clinical confounding factors and multiple comparisons, an association between genotype and disease-free survival (DFS) was shown for rs8086 in 3'-UTR of ACSL1 gene (HR 3.08; 95% CI 1.69-5.63; adjusted p = 0.046). Furthermore, the risk T/T genotype had significantly higher ACSL1 gene expression levels than patients carrying C/T or C/C genotype (means = 5.34; 3.73; 2.37 respectively; p-value (ANOVA) = 0.019), suggesting a functional role of this variant. Thus, we have identified a "risk genotype" of ACSL1 gene that confers constitutive high levels of the enzyme, which is involved in the activation of fatty acids through conversion to acyl-CoA and has been recently related to increased invasiveness of tumor cells. These results suggest that rs8086 of ACSL1 could be a promising prognostic marker in CC patients, reinforcing the relevance of LM in the progression of CC.
Collapse
Affiliation(s)
- Teodoro Vargas
- Molecular Oncology, IMDEA-Food Institute, CEI UAM+CSIC, Madrid, Spain
| | - Juan Moreno-Rubio
- Molecular Oncology, IMDEA-Food Institute, CEI UAM+CSIC, Madrid, Spain
- Precision Oncology Laboratory (POL), Infanta Sofía University Hospital, San Sebastián de los Reyes, Madrid, Spain
- Translational Oncology Laboratory, La Paz University Hospital (IdiPAZ), Madrid, Spain
| | - Jesús Herranz
- Biostatistics and Bioinformatics Unit, IMDEA-Food Institute, CEI UAM+CSIC, Madrid, Spain
| | - Paloma Cejas
- Translational Oncology Laboratory, La Paz University Hospital (IdiPAZ), Madrid, Spain
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America
| | - Susana Molina
- Molecular Oncology, IMDEA-Food Institute, CEI UAM+CSIC, Madrid, Spain
| | - Marta Mendiola
- Translational Oncology Laboratory, La Paz University Hospital (IdiPAZ), Madrid, Spain
| | - Emilio Burgos
- Pathology Department, La Paz University Hospital (IdiPAZ), Madrid, Spain
| | - Ana B. Custodio
- Medical Oncology, La Paz University Hospital (IdiPAZ), Madrid, Spain
| | - María De Miguel
- Translational Oncology Laboratory, La Paz University Hospital (IdiPAZ), Madrid, Spain
| | | | - Guillermo Reglero
- Molecular Oncology, IMDEA-Food Institute, CEI UAM+CSIC, Madrid, Spain
| | - Jaime Feliu
- Medical Oncology, La Paz University Hospital (IdiPAZ), Madrid, Spain
| | | |
Collapse
|
3
|
Silva CB, Rondon JN, Souza PF, Oliveira AMR, Santos GO, Kulik JD, Lima CP, Kerber VA, Dias JFG, Zanin SMW, Miguel OG, Miguel MD. The presence of Microlobius foetidus cause changes in the antioxidant defense of Urochloa decumbens? BRAZ J BIOL 2015; 75:565-73. [PMID: 26465722 DOI: 10.1590/1519-6984.16513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2013] [Accepted: 04/17/2014] [Indexed: 11/21/2022] Open
Abstract
Urochloa decumbens (Stapf) R. D. Webster (Poaceae) is an exotic species with has spread rapidly through the Cerrado area of Pantanal, Mato Grosso do Sul, Brazil. It has covered the soil aggressively turning it into cultivated pastures. Thus, it has become a challenge to protect native areas due its capacity of exclusion of native species. It has been observed that Microlobius foetidus (Jacq.) M.Sousa & G.Andrade species (Fabaceae) shows a dominant pattern over the development of U. decumbens. This work shows that M. foetidus interfere on the natural growth of U. decumbens within 10 m ratio. Between 15 and 20 m, it was observed an increase of Importance Value index (IVI) and Relative cover (RC) values. It was also observed a variation on the antioxidant defense system of U. decumbens within 10m ratio from M. foetidus. The enzymes superoxide dismutase, catalase and peroxidase present higher levels of activity then those found for glutathione reductase. This data indicates that M. foetidus may have an effect on U. decumbens, increase the activity of antioxidant enzymes. This effect probably happens as means to neutralize the toxic effects of the oxygen generated due to the presence of allelochemicals, which increases oxidative stress.
Collapse
Affiliation(s)
- C B Silva
- Departamento de Farmácia, Universidade Federal do Paraná, Curitiba, PR, BR
| | - J N Rondon
- Departamento de Biologia, Universidade Católica Dom Bosco, Campo Grande, MS, BR
| | - P F Souza
- Departamento de Biologia, Universidade Católica Dom Bosco, Campo Grande, MS, BR
| | - A M R Oliveira
- Departamento de Engenharia Florestal, Instituto Nacional de Pesquisas da Amazônia, Manaus, AM, BR
| | - G O Santos
- Departamento de Botânica, Universidade Federal do Paraná, Curitiba, PR, BR
| | - J D Kulik
- Departamento de Farmácia, Universidade Federal do Paraná, Curitiba, PR, BR
| | - C P Lima
- Departamento de Farmácia, Universidade Federal do Paraná, Curitiba, PR, BR
| | - V A Kerber
- Departamento de Farmácia, Universidade Federal do Paraná, Curitiba, PR, BR
| | - J F G Dias
- Departamento de Farmácia, Universidade Federal do Paraná, Curitiba, PR, BR
| | - S M W Zanin
- Departamento de Farmácia, Universidade Federal do Paraná, Curitiba, PR, BR
| | - O G Miguel
- Departamento de Farmácia, Universidade Federal do Paraná, Curitiba, PR, BR
| | - M D Miguel
- Departamento de Farmácia, Universidade Federal do Paraná, Curitiba, PR, BR
| |
Collapse
|